BAMBI GRILLEY to Genetic Therapy
This is a "connection" page, showing publications BAMBI GRILLEY has written about Genetic Therapy.
Connection Strength
1.923
-
How to democratize cell and gene therapy: A global approach. Mol Ther. 2025 May 07; 33(5):2082-2090.
Score: 0.664
-
Sickle cell disease gene therapy drug expenses and reimbursement: a litmus test for commercial pricing strategy and patient access for curative therapies. Cytotherapy. 2025 May; 27(5):567-570.
Score: 0.656
-
International Society for Cell & Gene Therapy Expanded Access Working Group position paper: key considerations to support equitable and ethical expanded access to investigational cell- and gene-based interventions. Cytotherapy. 2025 Jun; 27(6):671-677.
Score: 0.164
-
Gene transfer: regulatory issues and their impact on the clinical investigator and the good manufacturing production facility. Cytotherapy. 2003; 5(3):197-207.
Score: 0.142
-
Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease. Hum Gene Ther. 2000 Jul 01; 11(10):1465-75.
Score: 0.119
-
LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study. Lancet Oncol. 2024 Apr; 25(4):488-500.
Score: 0.039
-
International Society for Cell & Gene Therapy Position Paper: Key considerations to support evidence-based cell and gene therapies and oppose marketing of unproven products. Cytotherapy. 2023 09; 25(9):920-929.
Score: 0.037
-
An International Society for Cell & Gene Therapy working group short report on the future of expanded access to unapproved cell and gene therapies. Cytotherapy. 2023 07; 25(7):712-717.
Score: 0.036
-
Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trials. Mol Ther. 2023 03 01; 31(3):801-809.
Score: 0.035
-
Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma using an adenoviral vector. Hum Gene Ther. 2000 Jul 01; 11(10):1477-88.
Score: 0.030